Document Detail

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
MedLine Citation:
PMID:  7964944     Owner:  NLM     Status:  MEDLINE    
PURPOSE: This phase II study was conducted to evaluate the efficacy and toxicity of docetaxel in the treatment of patients with platinum-refractory ovarian cancer.
PATIENTS AND METHODS: Twenty-five patients with platinum-refractory advanced ovarian cancer were treated. Twenty of the patients had failed to respond to platinum-based front-line chemotherapy and five had failed to respond to platinum-based therapy repeated at relapse. One patient had received prior pelvic radiation therapy. Patients were required to have bidimensionally measurable disease. Docetaxel was administered at a dose of 100 mg/m2 intravenously (i.v.) over 1 hour every 21 days. Twenty patients received no corticosteroid premedication and five received premedication with corticosteroids and antihistamines.
RESULTS: Eight of 23 assessable patients (35%) had a partial response (PR; 95% confidence interval, 16% to 57%). The median response duration was 5 months. Hospitalization for toxicity, predominantly neutropenic fever, occurred in 12 patients (48%) and 16% of courses. Anemia was common in the study population. Nonhematologic toxicities included alopecia, rash, fluid retention, diarrhea, peripheral neuropathy, and hypersensitivity reactions.
CONCLUSION: Docetaxel demonstrates significant activity in patients with platinum-refractory advanced ovarian cancer. Routine premedication is recommended. Further investigations of this agent in ovarian cancer, including combinations with other active agents, appear indicated.
P Francis; J Schneider; L Hann; C Balmaceda; R Barakat; M Phillips; T Hakes
Related Documents :
15718314 - First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patient...
12399134 - Phase i trial of weekly docetaxel in elderly patients with non-small cell lung cancer.
17846704 - Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cance...
11263504 - Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a ...
7644924 - A phase i study of carboplatin and paclitaxel in non-small cell lung cancer: a universi...
9195494 - Oligoastrocytomas: a clinicopathological study of 52 cases.
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  12     ISSN:  0732-183X     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  1994 Nov 
Date Detail:
Created Date:  1994-12-02     Completed Date:  1994-12-02     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2301-8     Citation Subset:  IM    
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Phytogenic / adverse effects,  therapeutic use*
CA-125 Antigen / blood
Carboplatin / therapeutic use
Cisplatin / therapeutic use
Drug Resistance
Infusions, Intravenous
Middle Aged
Neutropenia / chemically induced
Ovarian Neoplasms / drug therapy*,  mortality
Paclitaxel / adverse effects,  analogs & derivatives*,  therapeutic use
Survival Analysis
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/CA-125 Antigen; 0/Taxoids; 15663-27-1/Cisplatin; 15H5577CQD/docetaxel; 33069-62-4/Paclitaxel; 41575-94-4/Carboplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatmen...
Next Document:  Squamous cell carcinoma antigen: prognostic significance and role in the monitoring of neoadjuvant c...